Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONTRIL PDM vs COPIKTRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies,Relapsed or refractory follicular lymphoma after at least two prior systemic therapies
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
25 mg orally twice daily
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 7–10 hours in patients with relapsed or refractory CLL/SLL. Steady-state is achieved within 3–5 days of twice-daily dosing.
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Primarily metabolized by CYP3A4; also involves CYP3A5 and UDP-glucuronosyltransferases (UGTs).
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Primarily via fecal excretion (approximately 70% of total dose) as unchanged drug and metabolites, with renal excretion accounting for <15% of the dose.
98% bound to albumin.
~84% bound to plasma proteins, primarily to albumin.
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
Mean apparent volume of distribution (Vz/F) is approximately 100–150 L (or ~1.4–2.1 L/kg based on typical body weight), indicating extensive tissue distribution.
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
Oral bioavailability is approximately 22% following a 25 mg capsule under fasting conditions. Absorption is increased with high-fat meals; therefore, it should be taken on an empty stomach.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min).
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild (Child-Pugh class A) or moderate (Child-Pugh class B), reduce dose to 25 mg once daily.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
Safety and efficacy in pediatric patients have not been established.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
No specific dose adjustment recommended for elderly patients, but monitor for adverse effects due to potential age-related renal or hepatic impairment.
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
WARNING: FATAL AND SERIOUS TOXICITIES: Fatal and serious toxicities including infections, diarrhea or colitis, cutaneous reactions, and pneumonitis have occurred with COPIKTRA.
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
Fatal and serious infections,Fatal and serious diarrhea or colitis,Fatal and serious cutaneous reactions,Fatal and serious pneumonitis,Neutropenia,Hepatotoxicity,Embryo-fetal toxicity
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
Concurrent use with strong CYP3A inhibitors due to increased toxicity risk
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
Avoid grapefruit and grapefruit juice; may increase dupilumab exposure. Take with or without food.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studies, duvelisib was embryotoxic and fetotoxic at maternal exposures below the recommended human dose. There are no adequate human data. Risks include embryo-fetal mortality, structural abnormalities, and growth impairment across all trimesters.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
No data on duvelisib presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions (e.g., immunosuppression, neutropenia), advise women not to breastfeed during treatment and for at least 1 month after last dose. M/P ratio unknown.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
No pharmacokinetic studies have been conducted in pregnant women. No dosing adjustments are recommended because duvelisib is contraindicated in pregnancy. If used inadvertently, the standard dose (25 mg twice daily) should be maintained until drug discontinuation is considered.
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
Monitor for hepatotoxicity with baseline and periodic liver function tests; avoid live vaccines; consider dose reduction in patients with moderate hepatic impairment (Child-Pugh B); watch for infections due to neutropenia; contraindicated in severe hepatic impairment (Child-Pugh C).
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection (fever, chills, cough) or jaundice (yellowing skin/eyes) immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not receive live vaccines during or shortly after treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONTRIL PDM vs COPIKTRA, answered by our medical review team.
BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. COPIKTRA is a PI3K Inhibitor Antineoplastic that works by Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONTRIL PDM and COPIKTRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. The standard adult dose of COPIKTRA is: 25 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONTRIL PDM and COPIKTRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . COPIKTRA is classified as Category C. COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.